Actuate Therapeutics, Inc. (ACTU)
(Delayed Data from NSDQ)
$7.31 USD
+0.24 (3.39%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $7.45 +0.14 (1.92%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ACTU 7.31 +0.24(3.39%)
Will ACTU be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ACTU based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for ACTU
Actuate: Elraglusib Continues To Deliver And Next Catalyst Is FDA Type B Meeting
Actuate Therapeutics files to sell 1.33M shares of common stock for holders
Actuate Therapeutics registers 1.33M shares for resale by investors
Actuate Therapeutics (ACTU) Plans to Issue 1.33 Million Shares of Common Stock
ACTU: Actuate Therapeutics Moves Towards Phase 2 Trial for Ewing Sarcoma | ACTU Stock News